Joseph Jorizzo, MD
Dermatology · Winston Salem, NCNPI 1316923360
Payments from drug & device makers
Across 16 payments — averaging $1268.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$13K
- Regeneron Healthcare Solutions, Inc.$4K
- Novartis$3K
- Johnson & Johnson$283
- Galderma Laboratories, L.p.$163
- LEO Pharma Inc.$65
- plus $53 from 2 others
What the payments were for
- Consulting fees$3,24016%
- Speaking & faculty fees$15,44476%
- Travel & lodging$9315%
- Food & beverage$3762%
- Education$2981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $12,625 |
| Regeneron Healthcare Solutions, Inc. | 2 | $3,861 |
| Novartis | 1 | $3,240 |
| Johnson & Johnson | 3 | $283 |
| Galderma Laboratories, L.p. | 2 | $163 |
| LEO Pharma Inc. | 1 | $65 |
| UCB, Inc. | 1 | $37 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$2,457
- EPIDUO FORTE$143
- ORACEA$143
How this compares
$20,289 in reported general payments places this provider in the 85th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 31 | $632,582 |
| Dupixent PenDupilumab | 158 | $572,754 |
| ThalomidThalidomide | 67 | $387,559 |
| Humira(Cf) PenAdalimumab | 28 | $198,214 |
| Dupixent SyringeDupilumab | 53 | $193,460 |
| Taltz AutoinjectorIxekizumab | 17 | $169,406 |
| Mycophenolate Mofetil | 175 | $13,908 |
| Clobetasol Propionate | 211 | $8,116 |
| Acitretin | 14 | $7,311 |
| Doxycycline Hyclate | 104 | $5,707 |
| Trifluoperazine Hcl | 96 | $4,648 |
| Triamcinolone Acetonide | 284 | $4,558 |
| Prednisone | 305 | $3,406 |
| SsdSilver Sulfadiazine | 84 | $2,664 |
| Desonide | 37 | $2,473 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Winston Salem
- Steven FeldmanWinston Salem$4.3M
- Kevin SteinWinston Salem$1.2M
- Amy McMichaelWinston Salem$762K
- David SpencerWinston Salem$34K
- Debra LiuWinston Salem$27K
- Rosalyn GeorgeWilmington$6.5M
- Adnan NasirRaleigh$4.1M
- Christopher SayedChapel Hill$3.3M
- Zoe DraelosHigh Point$3M
- Aida Lugo-SomolinosChapel Hill$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.